Colts keep 2021 league rushing champ Jonathan Taylor with 2-year, $44 million deal, AP source says

INDIANAPOLIS (AP) — Indianapolis Colts running back Jonathan Taylor got his wish.

A little more than a week after reiterating he wanted to stay with Indy for the rest of his career, Taylor took a big step toward fulfilling that pledge by signing a two-year, $44 million contract extension, a person with knowledge of the deal told The Associated Press on Thursday. The person requested anonymity because the team had not yet made an official announcement and does not release contract terms.

The move keeps the 2021 NFL rushing champ off the free agent market next spring and comes two days after the Atlanta Falcons re-signed Bijan Robinson to a record-breaking three-year deal worth up to $75 million.

Taylor never doubted the deal would get done before Indy's season opener Sept. 13 against Baltimore.

“I have faith. I mean, there’ve been some good conversations, and I have faith between my agent and the front office,” Taylor said last week when he arrived at training camp. "Like I said, I’ve already said I would love to be a Colt for life. So, I have faith that things are moving in the right direction.”

This deal follows two other big payouts this spring, to quarterback Daniel Jones and top receiver Alec Pierce, and keeps Indy's primary offensive players together long term.

Taylor is now under contract through 2028 and won't celebrate his 30th birthday until January 2029. Teams tend to devalue running backs after they turn 30.

By then, though, perhaps the conventional wisdom among teams will change. Taylor already has seen a notable difference in how teams value running backs since signing his last extension in 2023 when he didn't participate in camp as his agent and late team owner Jim Irsay engaged in a nasty public back-and-forth that resulted in Taylor requesting a trade.

Taylor struggled with injuries in 2022 and missed the first four games in 2023 with a lingering ankle injury. Since signing a three-year deal worth $42 million in early October 2023, he has missed just six of 41 games and has shown no signs of decline.

Taylor led the league in rushing most of last season while quarterback Daniel Jones played through a broken bone in his left leg before suffering a season-ending torn right Achilles tendon in early December. Taylor still finished third in the league with 1,585 yards and led the NFL with 18 touchdown runs.

Now he's seeing the payoff — and not just for himself.

“I think it’s a testament to how hard not only myself, but guys like Bijan, like a lot of the other top backs, they work really hard to put a great product on the field in order to reflect that value," Taylor said Wednesday before signing his new deal. "So obviously, still more work to be done. But man, that’s awesome for Bijan man. Shout out to Bijan, man. You earned it. You deserve it.”

The Colts also have made it clear how much they value Taylor.

From Jones and receiver Alec Pierce to coach Shane Steichen and general manager Chris Ballard, the consensus is that the threat of Taylor — as a both a runner and pass catcher — changes the way defenses must contend with the Colts.

The only real question was how quickly a deal could get done. Ballard is entering the final year of his contract as are left guard Quenton Nelson and defensive tackle DeForest Buckner. Taylor, Nelson and Buckner have all been selected to multiple Pro Bowls.

On July 28, report day at camp, Ballard said his contract status would have no impact on players' contract extensions.

“We always are working toward trying to keep our own players here, and I think you know my thoughts on both of them,” Ballard said when asked about Nelson and Taylor. "Quenton Nelson is a pillar, stands for all the right stuff, and Jonathan Taylor has been an excellent, excellent player for the Colts. I would love to have them long term. We’ll see.”

Now Taylor is in the fold for three more seasons.

The New Jersey prep star burst onto the scene with two 1,000-yard seasons with the Wisconsin Badgers. Leading up to the 2020 draft, critics contended Taylor was a risky early-round pick because of his college workload and questioned his pass-catching ability.

But the Colts selected Taylor in the second round, No. 41 overall, and an early-season injury to Marlon Mack forced Taylor into the starting lineup. He impressed right from the start, rushing for 1,169 yards and 11 TDs while catching 36 of 39 passes for 299 yards and another TD.

Taylor enters this season with 1,551 career carries, 7,598 yards, 69 TDs, 187 receptions, 1,469 yards and seven scores. He already owns the franchise record for touchdown runs and needs 1,629 yards rushing to surpass two-time NFL rushing champ Edgerrin James as the Colts career leader in that category, too.

Taylor also has the top two single-game rushing totals in franchise history, 253 against Jacksonville in January 2021 and 244 last season against Atlanta in Berlin.

AP NFL: https://apnews.com/hub/nfl

Indianapolis Colts running back Jonathan Taylor (28) runs a drill during practice at the NFL football team's training camp in Westfield, Ind., Thursday, July 30, 2026. (AP Photo/Michael Conroy)

Indianapolis Colts running back Jonathan Taylor (28) runs a drill during practice at the NFL football team's training camp in Westfield, Ind., Saturday, Aug. 1, 2026. (AP Photo/Michael Conroy)

WASHINGTON (AP) — The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, manufacturer Moderna said.

The shot, named mFlusiva, is intended for adults age 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.

While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable.

Flu vaccines must be updated annually to best match circulating strains of the virus. Vaccines made with the Nobel Prize-winning mRNA technology are faster to manufacturer than other types, and experts say this additional option might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses.

Moderna said the FDA granted full approval for mFlusiva’s use in people ages 50 to 64, based on a study of 40,000 people that found 27% fewer flu cases among people who got the new shot compared with those who got a different common flu vaccine brand. For people 65 or older, the Cambridge, Massachusetts-based manufacturer said the FDA granted what’s called accelerated approval for the shot -- based on a smaller study showing it generated a strong immune response compared with an existing high-dose vaccine for seniors – while it conducts an additional study.

Moderna’s data showed no major safety issues although the shot did cause some temporary reactions including injection site pain, fever, headache, tiredness and aches that occurred somewhat more than with today’s flu shots.

The FDA action comes after a highly unusual public dispute over mFlusiva earlier this year. A then-top FDA official blocked the company’s application, a sign of the agency’s heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr. Days later, the agency changed course after Moderna publicly challenged the ruling — and in June a panel of independent advisers to the FDA unanimously recommended the vaccine's approval.

Follow the AP's coverage of the U.S. Food and Drug Administration at https://apnews.com/hub/us-food-and-drug-administration.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, April 22, 2025. (AP Photo/Jose Luis Magana, File)